Comparative Pharmacology
Head-to-head clinical analysis: DIZAC versus NAYZILAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIZAC versus NAYZILAM.
DIZAC vs NAYZILAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dizac is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, resulting in increased chloride ion influx, neuronal hyperpolarization, and inhibition of neuronal excitability.
Nayzilam (midazolam) is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal activity.
10 mg IV/IM every 4-6 hours as needed; max 40 mg/day.
5 mg intranasally as a single dose; may repeat once after 10 minutes if needed. Maximum 10 mg per episode.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours in adults; prolonged in renal impairment (up to 20 hours in anuria), neonates, and elderly. Clinical context: Repeated dosing recommended every 4-6 hours.
Terminal elimination half-life of midazolam is 1.5–2.5 hours, but for NAYZILAM (midazolam nasal spray) the effective half-life for anticonvulsant effect is approximately 2–3 hours due to prolonged absorption; clinical context: used for seizure clusters, duration of effect may persist for 4–6 hours.
Renal (70-80% as unchanged drug and metabolites, primarily via glomerular filtration and active tubular secretion), biliary/fecal (15-20%)
Renal excretion as metabolites (primarily glucuronide conjugates) and unchanged drug; approximately 15% recovered in urine as unchanged midazolam, with the remainder as metabolites; <1% excreted in feces via biliary elimination.
Category C
Category C
Benzodiazepine
Benzodiazepine